CMXHF — CSL LTD

OTC · Unknown · Unknown · CIK 1274152 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2024 8,213,000,000 4,279,000,000 1,977,000,000 2,007,000,000 38,447,000,000 1,524,000,000 17,901,000,000

Balance + Analyst (yfinance extras)

Retained Earnings
$17,331,000,000
Inventory
$6,139,000,000
Receivables
$3,606,000,000
ST Investments
EBIT TTM
$2,753,000,000
Pretax Income TTM
$2,540,000,000
Interest Exp TTM
$213,000,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$15,406,999,552
EBITDA
$4,840,000,000
Free Cash Flow
$1,848,125,056
Enterprise Value
$45,192,249,344
Total Cash
$1,144,999,936
Total Debt
$11,137,999,872
Shares Out
478,911,979
Trailing EPS
$6.17
Book Value
$38.70
ROE
6.7%
ROA
6.6%
Div Yield
4.17%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025 15,430,000,000 2,959,000,000 3,002,000,000 39,404,000,000 17,997,000,000
Jun 2024 14,690,000,000 2,764,000,000 2,642,000,000 38,022,000,000 18,621,000,000
Jun 2023 13,174,000,000 2,102,000,000 2,194,000,000 36,234,000,000 18,408,000,000
Jun 2022 10,493,100,000 2,316,100,000 2,254,700,000 28,346,000,000 13,768,500,000

Peers — same industry

TickerNameMarket CapLastDaily %
SPY SPDR S&P 500 ETF TRUST $688.88B $750.59
KLAC KLA CORP $262.74B $2011.39
IBM INTERNATIONAL BUSINESS MACHINES CORP $235.62B $250.69
KXIAY Kioxia Holdings Corporation/ADR $231.81B $42.45
SMEGF Siemens Energy AG/ADR $180.38B $212.00

News headlines (Yahoo Finance, 1h cache)

Imugene strengthens board with biotech and pharma appointments
2026-05-26 00:56 · Yahoo
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada
2026-05-20 10:00 · Yahoo
3 ASX Dividend Stocks Yielding Up To 4.2%
2026-05-18 19:39 · Yahoo
CSL Plunges 22% After Cutting Outlook And Flagging $5 Billion Impairments
2026-05-11 12:38 · Yahoo
Should Value Investors Buy CSL Limited (CSLLY) Stock?
2026-05-04 13:40 · Yahoo
CSL Restructure And Seqirus Split Reset Expectations After Share Price Slide
2026-05-02 06:15 · Yahoo
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
2026-04-30 15:40 · Yahoo
CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?
2026-04-14 15:40 · Yahoo
CSLLY or ARGX: Which Is the Better Value Stock Right Now?
2026-03-24 15:40 · Yahoo
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
2026-03-23 15:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.